



Press Release from ROVI

ROVI's Alcalá de Henares plant receives the visit of the Romanian Health Minister

- The minister, Alexandru Rafila, was accompanied by the Chief of Staff of the Romanian Health Ministry and the Romanian ambassador to Spain
- The Alcalá de Henares plant is one of the three ROVI plants engaged in contract manufacturing, a strategic area for the company with its sales associated to a high degree of internationalisation
- The high manufacturing capacity and technological differentiation available at its facilities allows ROVI to respond to the growing trend among pharmaceutical companies to outsource their manufacturing processes

Madrid, 6th February, 2023

This Monday, the Romanian Minister of Health, Alexandru Rafila, visited the ROVI plant in Alcalá de Henares. The Chief of Staff of the Romanian Health Ministry, Raluca Puiu, and the Romanian ambassador to Spain, George Gabriel Bologan, were also present. The Romanian authorities were accompanied by ROVI's Chairman and Chief Executive Officer, Juan López-Belmonte, the Industrial Manager, Miguel Ángel Ortega, and the Manager of the Alcalá de Henares plant, Pilar García-Morato Saro.

The ROVI plant in Alcalá de Henares is one of the Laboratory's three plants engaged in the CMO (contract manufacturing organisation) business, the purpose of which is to respond to the growing need for pharmaceutical companies to outsource their manufacturing processes. The Alcalá plant specialises in the production of oral solid forms and has become a centre of excellence for the group's packaging of both solid products and injectables.

ROVI is one of the main sector companies in the high value-added CMO business, with exports to over 50 countries. The majority of its sales are international and it is highly technologically specialised in the area of manufacturing vaccines, biological

products and biosimilars, all of which are products with a recognised therapeutic value.

During the visit, the Romanian Health Minister, Alexandru Rafila, observed the plant's manufacturing processes in detail and met with Juan López-Belmonte, the Chairman and Chief Executive Officer of ROVI.

About ROVI

ROVI is a pan-European pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Poland and has a diversified marketing portfolio of more than 40 products, among which its flagship product, Bemiparin, which is present in more than 60 countries all over the world, stands out. Likewise, in 2017, ROVI began to market its enoxaparin biosimilar, developed in-house, in Europe and it is already being marketed in 38 countries. ROVI is continuing to develop the ISM® platform technology, a leading edge line of research in the field of prolonged drug release, with proven advantages. For further information, please visit www.rovi.es.